Endpoints News: FDA delays PDUFA date for Libtayo lung cancer combo; Swedish biotech hit flunks PhIII for chemo-enhancing drug.

“We recently were informed that an FDA travel complication relating to scheduling a routine clinical trial site inspection in Eastern Europe will likely delay their decision until after our September 19 PDUFA date,” Regeneron president and CEO Len Schleifer said during the call.

He added that a new inspection date has already been scheduled, so the delay shouldn’t be too lengthy and that Regeneron doesn’t “expect it to meaningfully impact our launch plans assuming FDA approval.”

https://endpts.com/fda-delays-pdufa-date-for-libtayo-lung-cancer-combo-swedish-biotech-hit-flunks-phiii-for-chemo-enhancing-drug/

Sent via the Samsung Galaxy Z Fold3 5G, an AT&T 5G smartphone
Get Outlook for Android